Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Angiogenesis is a hallmark of cancer and is required for tumor growth and progression.
Antiangiogenic therapy has been revolutionarily developing and was approved for the …

Acting on the cytokine cascade is key to preventing disease progression and death in
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …

Acute respiratory distress syndrome (ARDS) is an acute inflammatory condition with a
dramatic increase in incidence since the beginning of the coronavirus disease 19 (COVID …

COVID-19 has claimed millions of lives during the last 3 years since initial cases were
reported in Wuhan, China, in 2019. Patients with COVID-19 suffer from severe pneumonia …

Background Dysregulated inflammation is associated with poor outcomes in COVID-19. We
aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating …

Macrophages play diverse roles in development, homeostasis, and immunity. Accordingly,
the dysfunction of macrophages is involved in the occurrence and progression of various …

GM-CSF promotes myelopoiesis and inflammation, and GM-CSF blockade is being
evaluated as a treatment for COVID-19-associated hyperinflammation. Alveolar GM-CSF is …

Background Imatinib reduced 90-day mortality in hospitalised coronavirus disease 2019
(COVID-19) patients in a recent clinical trial, but the biological effects that cause improved …

Acute respiratory distress syndrome (ARDS) is a heterogeneous cause of respiratory failure
that has a rapid onset, a high mortality rate, and for which there is no effective …